Overview

VX-950-TiDP24-C219: A Roll Over Trial for Patients in the Control Group of the C216 Study Who Received Telaprevir Placebo

Status:
Completed
Trial end date:
2012-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to provide access to telaprevir for patients from the control group in the C216 study, who failed treatment for virologic reasons. Efficacy, safety and tolerability of telaprevir in combination with standard treatment will be evaluated.
Phase:
Phase 3
Details
Lead Sponsor:
Janssen Infectious Diseases BVBA
Collaborator:
Vertex Pharmaceuticals Incorporated
Treatments:
Interferons
Peginterferon alfa-2a
Ribavirin